Artificial intelligence is rapidly transforming FDA-regulated industries—but it is also quietly reshaping regulatory risk.
Companies across food, beverage, dietary supplements, OTC drugs, cosmetics, and medical devices are now using AI to draft submissions, generate SOPs, review labels, and analyze safety data. At the same time, FDA itself is deploying AI to accelerate review, inspections, and enforcement activities.
The takeaway is not that AI is risky.
The takeaway is that AI changes the compliance equation—and raises the bar.
The New Rule: AI Is Allowed. Blind Reliance Is Not.
FDA’s emerging posture is consistent across product categories:
- AI can support regulatory decision-making
- AI outputs must be validated, documented, and fit-for-purpose
- Human accountability never shifts to the algorithm
FDA’s 2025 draft guidance makes this explicit, requiring a risk-based credibility framework for AI used to support safety, effectiveness, or quality determinations.
But enforcement tells the real story.
In a 2026 warning letter, FDA cited a firm for relying on AI-generated procedures without proper review—emphasizing that all such outputs must be reviewed and approved by qualified personnel under cGMP (e.g., 21 CFR § 211.22).
AI did not fail the company. Governance did.
Where Companies Are Using AI (and Where Risk Creeps In)
AI adoption is no longer limited to pharma. It now touches nearly every FDA-regulated workflow:
Food, Beverage, Dietary Supplements
- Label compliance checks
- Ingredient and claim screening
- Adverse event trend analysis
Risk: AI-generated claim substantiation or labeling conclusions that rely on incomplete or non-authoritative sources.
- Drug Facts label drafting
- Monograph interpretation
- Pharmacovigilance support
Risk: AI outputs influencing labeling or safety determinations without validation or documentation—triggering full regulatory expectations.
Cosmetics & Personal Care (MoCRA)
- Ingredient safety summaries
- Adverse event intake and trending
- Registration and listing support
Risk: AI synthesizing safety conclusions without adequate substantiation—particularly problematic under MoCRA’s safety substantiation standard.
Medical Devices (Including AI-Enabled Products)
- Design, validation, and documentation of AI-enabled software
- Real-world performance monitoring
- Submission preparation
FDA now expects full lifecycle controls for AI systems, including transparency, bias mitigation, and postmarket monitoring.
Translation: If AI affects product performance or regulatory decisions, it is treated like regulated technology—not a convenience tool.
The Achilles’ Heel of AI: It Sounds Right (Even When It’s Wrong)
Generative AI introduces risks that are uniquely dangerous in FDA compliance:
- Hallucinations: Plausible—but incorrect—regulatory statements or citations
- Opacity: Limited ability to explain how outputs were generated
- Data quality issues: Bias, gaps, and non-authoritative sources
- Confidentiality exposure: Risk of disclosing proprietary or trade secret data through prompts
None of these are theoretical. They directly map onto FDA’s core expectations: accuracy, traceability, and data integrity.
Human Review Is Not Optional—It Is the Control
FDA has made one point unmistakably clear:
AI outputs must be reviewed and approved by humans with appropriate authority.
That includes:
- Quality Unit review for GMP documents
- Regulatory Affairs review for submissions and labeling
- Legal review for claims, classification, and enforcement risk
Even when AI is used correctly, the legal and regulatory responsibility does not move.
What “Defensible AI Use” Looks Like
Companies using AI in regulated environments should assume their practices will be scrutinized—and build accordingly:
- Validate the Tool (Not Just the Output)
- Define intended use and regulatory impact
- Apply a risk-based credibility framework
- Document model limitations and performance
- Embed Human-in-the-Loop Controls
- Require expert review for all AI-generated regulatory content
- Ensure Quality and Regulatory sign-off for GxP-impacting outputs
- Treat AI as Part of the Quality System
- Incorporate AI into SOPs, training, and change control
- Maintain audit trails for outputs and decisions
- Lock Down Data Governance
- Avoid entering confidential data into uncontrolled AI tools
- Implement policies for prompt use and data handling
Why FDA Counsel Review Matters Is Non-Negotiable
Even with technical validation and quality controls, AI cannot interpret law.
FDA counsel plays a distinct and critical role in:
- Determining regulatory classification (e.g., dietary supplement vs. drug vs. device)
- Interpreting ambiguous guidance, enforcement trends, and inspection risk
- Reviewing claims, labeling, and promotional language
- Identifying legal exposure from AI-generated content
This is particularly important because:
- FDA expectations are evolving rapidly
- AI tools often rely on generalized or outdated regulatory frameworks
- Legal risk frequently arises from context and interpretation—not just data accuracy
Put bluntly: An AI-generated answer can be technically correct and still legally wrong.
Bottom Line
AI is now embedded in FDA-regulated industries—and its use will only accelerate.
But the compliance rule has not changed: You can use AI to do the work. You cannot rely on AI to own the outcome.
Companies that treat AI outputs as inherently reliable—or fail to subject them to rigorous quality and legal review—are effectively outsourcing compliance to an unvalidated system. FDA has already shown that this is not acceptable.
The winning strategy is disciplined adoption: AI + validation + human expertise + legal review.
Anything less is not innovation—it is exposure.
For more information on AI and FDA compliance, or for FDA compliance or enforcement questions, please contact info@garg-law.com.
